Cilofexor in Patients With Compensated Cirrhosis Due to Primary Sclerosing Cholangitis: An Open-Label Phase 1B Study.
Cynthia LevyStephen CaldwellParvez MantryVelimir LuketicCharles S LandisJonathan HuangEdward MenaRahul MaheshwariKevin RankJun XuVladislav A MalkovAndrew N BillinXiangyu LiuXiaomin LuWilliam T BarchukTimothy R WatkinsChuhan ChungRobert P MyersKris V KowdleyPublished in: Clinical and translational gastroenterology (2024)
Escalating doses of cilofexor over 12 weeks were well tolerated and improved cholestasis markers in patients with compensated cirrhosis due to primary sclerosing cholangitis (NCT04060147).
Keyphrases